The present study was undertaken to compare the effectiveness of a new water-soluble benzodiazepine, midazolam, to diazepam, both administered im for protection against diethyl-p-nitrophenyl phosphate (paraoxon) toxicity. Adult male Sprague-Dawley rats were pretreated with midazolam or diazepam (0.32-32.0 mg/kg) alone or in combination with atropine (10.0 mg/kg). Twenty minutes later 2 X LD50 of paraoxon was injected sc and the incidence of seizures and death were recorded for 24 hr. In another series of experiments, the LD50 of paraoxon was evaluated in the rats pretreated im with atropine (10.0 mg/kg) and midazolam or diazepam (10.0 mg/kg). Pretreatment with atropine alone did not prevent paraoxon-induced seizures but did reduce mortality. Both benzodiazepines were very effective alone or when combined with atropine in reducing the incidence of paraoxon-induced seizures. When given alone, neither benzodiazepine protected against paraoxon-induced mortality. However, when combined with atropine both benzodiazepines dramatically decreased the lethality of 2 X LD50 of paraoxon. In equal doses given im, midazolam proved to be more potent than diazepam.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0041-008x(85)90425-9 | DOI Listing |
Vet Anaesth Analg
December 2024
Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA, USA; Kenneth L. Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California, Davis, CA, USA.
Objective: To model pharmacokinetics of three benzodiazepines and their metabolites in sheep.
Study Design: A nonblinded, prospective, experimental study.
Animals: A group of six adult Hampshire-Suffolk cross-bred sheep (three females, three castrated males), 73 ± 3 kg (mean ± standard deviation).
Epilepsy Res
January 2025
Department of Neurology, Vaasa Central Hospital, Vaasa, Finland.
Background: Status epilepticus (SE) is a life-threatening state that needs rapid and adequate treatment. Benzodiazepines (BZD) are used as a first-line treatment for SE, and if the desired effect is not achieved, second-line antiseizure medications are used.
Objective: To investigate whether the treatment with BZDs is performed adequately in patients with different subtypes of SE requiring second-line ASM treatment and, if not, to identify the factors influencing the suboptimal treatment.
Neurotherapeutics
December 2024
Department of Neurology and Neuroscience Brain Institute University of Virginia, School of Medicine, Health Sciences Center, Box 801330, Charlottesville, VA 22908-1330, USA. Electronic address:
Generalized Convulsive status epilepticus (SE) is a neurological emergency because prolonged convulsions can cause respiratory compromise and neuronal injury. Compromised GABA-mediated inhibition is a defining feature of SE, and many current therapies are benzodiazepines, which are allosteric modulators of GABA-A receptors. Many patients with medically refractory epilepsy are at risk for SE.
View Article and Find Full Text PDFEpilepsia Open
December 2024
Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Since 2018, three new antiseizure medications (ASMs) received FDA approval for Dravet syndrome (DS) in the U.S: cannabidiol, stiripentol, and fenfluramine. Yet, the uptake of these ASMs in routine clinical practice is unknown.
View Article and Find Full Text PDFBrain Dev
December 2024
Working Group for the Revision of Treatment Guidelines for Pediatric Status Epilepticus/Convulsive Status Epilepticus, Japanese Society of Child Neurology, Tokyo, Japan; Committee for Integration of Guidelines, Japanese Society of Child Neurology, Tokyo, Japan; Division of Child Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!